Clinical Trial Update: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial [Phase 1]

View source ↗

Summary

The ARCHON-1 phase 1 trial updates on the safety of adding either Monalizumab or Oleclumab to Durvalumab with standard radiation therapy for locally advanced or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Monalizumab (IPH2201) (monalizumab)
• Oleclumab (MEDI9447) (oleclumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-06-19